The race for the corona vaccine has already started and many leading companies are coming to the fore. The US government has granted $486 million to AstraZeneca Plc to expand and secure quantities of up to 100,000 doses of Covid-19 antibody treatment, a similar class of drug that was used in treating President Donald Trump. The agreement, under the Trump administration’s Operation Warp Speed, is for developing a monoclonal antibody cocktail that can prevent Covid-19, especially in high-risk populations like those over 80 years old, the US Department of Health and Human Services responded.

'China has deployed 60,000 troops at Indian border' claims US Foreign Minister Mike Pompeo

The treatment has come under the spotlight after Trump was treated with Regeneron Pharmaceuticals’ antibody-drug last week. The president has also released a video on Twitter touting its benefits. In a call earlier on Friday, a top US health official said the government was awaiting to provide more than 1 million free doses of antibody treatments to Covid-19 patients, similar to the one that was administered to Trump. Regeneron and Eli Lilly have both applied to the US Food and Drug Administration for emergency use authorizations of their antibody treatments.

US Foreign Minister Mike Pompeo said this to India regarding China

AstraZeneca said it was preparing to supply up to 100,000 doses starting toward the end of 2020 and that the US government could acquire up to an additional one million doses in 2021 under a separate agreement. Regeneron approved a $450 million deal in July to sell Operation Warp Speed enough doses of its antibody treatment, REGN-COV2, to treat around 300,000 people. Eli Lilly said on Friday it had not signed an agreement with Operation Warp Speed. AstraZeneca plans to evaluate the treatment, AZD7442, which is a cocktail of two monoclonal antibodies, in two studies.

USA: Presidential debate programmed for Oct 15 gets canceled